Clinical Trial Update: Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating olaparib alone and in combination with pembrolizumab for ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Olaparib (Olaparib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: National Cancer Center Hospital East | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED